Sugi Predict

Sugi Predict / Compounds / SCHEMBL56907

SCHEMBL56907

SCHEMBL56907

COC(=O)[C@@H](CC(C)C)NC(=O)OC(C)(C)C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSL P07711 2/20 0.60
▸ CTSK P43235 2/20 0.60
▸ CTSB P07858 1/20 0.60
▸ CTSS P25774 1/20 0.60
▸ CAPN1 P07384 1/20 0.52
▸ CA1 P00915 1/20 0.51
▸ CA2 P00918 1/20 0.51
▸ CA7 P43166 1/20 0.51
▸ PSEN1 P49768 2/20 0.49
▸ PSEN2 P49810 2/20 0.49
▸ APH1B Q8WW43 2/20 0.49
▸ NCSTN Q92542 2/20 0.49
▸ APH1A Q96BI3 2/20 0.49
▸ PSENEN Q9NZ42 2/20 0.49
▸ TAS1R3 Q7RTX0 1/20 0.48
▸ TAS1R1 Q7RTX1 1/20 0.48
▸ AAK1 Q2M2I8 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ POLB P06746 2/20 0.46
▸ BIRC2 Q13490 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL55833 1.00 CTSL (0.60) CTSLCTSKCTSBCTSSCAPN1
SCHEMBL55832 1.00 CTSL (0.60) CTSLCTSKCTSBCTSSCAPN1
SCHEMBL1026997 0.94 CTSL (0.62) CTSLCTSKCTSBCTSSCAPN1
SCHEMBL1176795 0.94 CTSL (0.62) CTSLCTSKCTSBCTSSCAPN1
SCHEMBL1026994 0.94 CTSL (0.62) CTSLCTSKCTSBCTSSCAPN1
SCHEMBL21675512 0.91 CTSK (0.61) CTSLCTSKCTSBCTSSCAPN1
SCHEMBL23080082 0.90 CTSL (0.54) CTSLCTSKCTSBCTSSCAPN1
SCHEMBL16668218 0.90 CTSL (0.54) CTSLCTSKCTSBCTSSCAPN1
SCHEMBL6897731 0.90 CTSK (0.60) CTSLCTSKCTSBCTSSCAPN1
SCHEMBL12588811 0.89 CTSL (0.53) CTSLCTSKCTSBCTSSCAPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4685151-A1 PROTEASOME INHIBITOR Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2026-01-28 — — EP disclosed
US-20240018161-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2024-01-18 — — US disclosed
US-20240018161-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2024-01-18 — — US disclosed
CN-116670143-A Modulators of cystic fibrosis transmembrane conductance regulator 弗特克斯药品有限公司 2023-08-29 — — CN disclosed
EP-4225447-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 — — EP disclosed
US-20220177471-A1 N-1 BRANCHED ALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2022-06-09 — — US disclosed
WO-2022076625-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
WO-2022076625-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
EP-3980415-A1 N-1 BRANCHED ALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS 3M Innovative Properties Company (US) 2022-04-13 — — EP disclosed
CN-113924297-A N-1 branched alkyl substituted imidazo [4,5-c ] quinoline compounds, compositions, and methods 3M创新有限公司 2022-01-11 — — CN disclosed
US-20130313669-A1 AMINO ACID GENERATOR AND POLYSILOXANE COMPOSITION CONTAINING THE SAME NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2013-11-28 — — US disclosed
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 — — US disclosed
EP-2420491-A1 3 , 5-substitued piperidine compounds as renin inhibitors Novartis AG (CH) 2012-02-22 — — EP disclosed
CN-102037092-A Amino acid generator and polysiloxane composition containing the same NISSAN CHEMICAL IND LTD 2011-04-27 — — CN disclosed
US-20110073977-A1 AMINO ACID GENERATOR AND POLYSILOXANE COMPOSITION CONTAINING THE SAME NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2011-03-31 — — US disclosed
US-7642369-B2 Reacting Boc-Leu-OMe with dimethyl methylphosphonate treated with tert-butyllithium, formaldehyde and potassium oxide to produce the hydroxymethyl-substituted enone; multi-step peptide coupling to form dihydroeponemycin analogues; angiogenesis inhibitors; Alzheimer's and Huntington's Diseases UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2010-01-05 — — US disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 — — US disclosed
EP-1968940-A1 3 , 5-SUBSTITUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS Novartis AG (CH) 2008-09-17 — — EP disclosed
US-20080064659-A1 EPOXYKETONE-BASED IMMUNOPROTEASOME INHIBITORS UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2008-03-13 — — US disclosed
WO-2007077005-A1 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS NOVARTIS AG (CH) 2007-07-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064659-A1 EPOXYKETONE-BASED IMMUNOPROTEASOME INHIBITORS PSME2, PSMB2, PSME1 CTSL 965/4885CTSK 198/4885CTSB 426/4885
US-20240018161-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B CTSL 3165/4885CTSK 2874/4885CTSB 3003/4885
US-20090192148-A1 Organic Compounds REN, ACE, AGTR1 CTSL 432/4885CTSK 863/4885CTSB 485/4885
US-20110073977-A1 AMINO ACID GENERATOR AND POLYSILOXANE COMPOSITION CONTAINING THE SAME DAO, BCAT1, BCAT2 CTSL 1088/4885CTSK 2277/4885CTSB 2197/4885
US-20220177471-A1 N-1 BRANCHED ALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS IFNG, IFNAR1, IRF3 CTSL 2064/4885CTSK 3049/4885CTSB 2350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.